<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?><document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="3bdffc8e-b908-4827-b941-31a1f7063125"/>
   <code code="60683-0" codeSystem="2.16.840.1.113883.6.1" displayName="PLASMA DERIVATIVE"/>
   <title> FEIBA NF (Anti-Inhibitor Coagulant Complex)</title>
   <effectiveTime value="20110623"/>
   <setId root="70a31431-1a44-4415-84ec-c91897ffac17"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="085206634" root="1.3.6.1.4.1.519.1"/>
            <name>Baxter Healthcare Corporation</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="300434670" root="1.3.6.1.4.1.519.1"/>
                        <name>Baxter Aktiengesellschaft</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="001728059" root="1.3.6.1.4.1.519.1"/>
                        <name>Baxter Healthcare Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="75bf3150-b748-4b63-a71c-29f931127a4d"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20110623"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="64193-223" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>FEIBA<suffix>NF</suffix>
                        </name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Anti-Inhibitor Coagulant Complex</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="64193-223-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                           </containerPackagedProduct>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="mL" value="25"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="64193-323" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>FEIBA<suffix>NF</suffix>
                              </name>
                              <formCode code="C42973" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, FOR SOLUTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Anti-Inhibitor Coagulant Complex</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="[USP'U]" value="25"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="CS849DUN3M" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ANTI-INHIBITOR COAGULANT COMPLEX</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="CS849DUN3M" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>ANTI-INHIBITOR COAGULANT COMPLEX</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="4"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TRISODIUM CITRATE DIHYDRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="8"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM CHLORIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="25"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="64193-323-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                                 </containerPackagedProduct>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA101447" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="19860131"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator unit="mL" value="20"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0338-0764" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Sterile Water</name>
                              <formCode code="C42953" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LIQUID"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>water</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mL" value="20"/>
                                    <denominator unit="mL" value="50"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="20"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0338-0764-62" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43209" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, GLASS"/>
                                 </containerPackagedProduct>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA101447" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="19860131"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA101447" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19860131"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="64193-224" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>FEIBA<suffix>NF</suffix>
                        </name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Anti-Inhibitor Coagulant Complex</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="64193-224-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                           </containerPackagedProduct>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="mL" value="50"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="64193-324" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>FEIBA<suffix>NF</suffix>
                              </name>
                              <formCode code="C42973" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, FOR SOLUTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Anti-Inhibitor Coagulant Complex</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="[USP'U]" value="50"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="CS849DUN3M" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ANTI-INHIBITOR COAGULANT COMPLEX</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="CS849DUN3M" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>ANTI-INHIBITOR COAGULANT COMPLEX</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="4"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TRISODIUM CITRATE DIHYDRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="8"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM CHLORIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="50"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="64193-324-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                                 </containerPackagedProduct>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA101447" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="19860131"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator unit="mL" value="20"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0338-0764" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Sterile Water</name>
                              <formCode code="C42953" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LIQUID"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Water</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mL" value="20"/>
                                    <denominator unit="mL" value="50"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="20"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0338-0764-62" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43209" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, GLASS"/>
                                 </containerPackagedProduct>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA101447" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="19860131"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA101447" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19860131"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="64193-225" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>FEIBA<suffix>NF</suffix>
                        </name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Anti-Inhibitor Coagulant Complex</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="64193-225-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                           </containerPackagedProduct>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="mL" value="50"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="64193-325" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>FEIBA</name>
                              <formCode code="C42973" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, FOR SOLUTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Anti-Inhibitor Coagulant Complex</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="[USP'U]" value="50"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="CS849DUN3M" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ANTI-INHIBITOR COAGULANT COMPLEX</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="CS849DUN3M" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>ANTI-INHIBITOR COAGULANT COMPLEX</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="4"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TRISODIUM CITRATE DIHYDRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="8"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM CHLORIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="50"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="64193-325-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                                 </containerPackagedProduct>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA101447" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="19860131"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator unit="mL" value="50"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0338-0001" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Sterile Water</name>
                              <formCode code="C42953" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LIQUID"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Water</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mL" value="50"/>
                                    <denominator unit="mL" value="100"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="50"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0338-0001-65" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43209" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, GLASS"/>
                                 </containerPackagedProduct>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA101447" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="19860131"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA101447" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19860131"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="i4i_section_id_42272776-72ec-4e19-8001-51363c7f184a">
               <id root="4e75f43d-08f3-48de-99e9-072ef1a78df5"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph> </paragraph>
                  <paragraph>
                     <content styleCode="bold">Nanofiltered
                                and Vapor Heated </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Lyophilized powder for solution</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Intravenous</content>
                  </paragraph>
               </text>
               <effectiveTime value="20110623"/>
               <component>
                  <section ID="id_5a6ea4d8-55a7-4e4f-a9c4-9e76bb8902bb">
                     <id root="6042c392-b4dd-4564-9b4e-580a5d7aec39"/>
                     <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="Boxed Warning section"/>
                     <title>WARNING</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Thrombotic and thromboembolic
                                        events have been reported during postmarketing surveillance
                                        following infusion of FEIBA VH or FEIBA NF, particularly
                                        following the administration of high doses and/or in
                                        patients with thrombotic risk factors (See WARNINGS,
                                        PRECAUTIONS and ADVERSE
                                REACTIONS).</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20110623"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_description_id_7649ec3e-40dc-40e5-b52a-1096d1a0d223">
               <id root="d5eee024-b31d-4511-8b22-870d49fa4cb2"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>FEIBA NF (Anti-Inhibitor Coagulant Complex), nanofiltered and
                            vapor heated, is a freeze-dried sterile human plasma fraction with
                            Factor VIII inhibitor bypassing activity.<content styleCode="italics">
                                In vitro</content>, FEIBA NF shortens the activated partial
                            thromboplastin time (APTT) of plasma containing Factor VIII inhibitor.
                            Factor VIII inhibitor bypassing activity is expressed in arbitrary
                            units. One unit of activity is defined as that amount of FEIBA NF that
                            shortens the APTT of a high titer Factor VIII inhibitor reference plasma
                            to 50% of the blank value. </paragraph>
                  <paragraph>FEIBA NF contains
                            Factors II, IX, and X, mainly non-activated, and Factor VII mainly in
                            the activated form. The product contains approximately equal unitages of
                            Factor VIII inhibitor bypassing activity and Prothrombin Complex
                            Factors. In addition, 1–6 units of Factor VIII coagulant antigen (FVIII
                            C:Ag) per mL are present. The preparation contains only traces of
                            factors of the kinin generating system. It contains no
                            heparin.</paragraph>
                  <paragraph>Reconstituted FEIBA NF contains 4 mg of
                            trisodium citrate and 8 mg of sodium chloride per
                            mL.</paragraph>
                  <paragraph>FEIBA NF is manufactured from large plasma
                            pools of human plasma. Screening against potentially infectious agents
                            begins with the donor selection process and continues throughout plasma
                            collection and plasma preparation. Each individual plasma donation used
                            in the manufacture of FEIBA NF is collected only at FDA approved blood
                            establishments and is tested by FDA licensed serological tests for
                            Hepatitis B Surface Antigen (HBsAg), and for antibodies to Human
                            Immunodeficiency Virus (HIV-1/HIV-2) and Hepatitis C Virus (HCV) in
                            accordance with the U.S. regulatory requirements. As an additional
                            safety measure, mini-pools of the plasma are tested for the presence of
                            HIV-1 and HCV by FDA licensed Nucleic Acid Testing (NAT) and found
                            negative. In addition, two dedicated and independent virus
                            removal/inactivation steps have been integrated into the manufacturing
                            process, namely 35 nm nanofiltration and a vapor heat treatment process.
                            In addition, the DEAE-Sephadex adsorption contributes to the virus
                            safety profile of FEIBA NF. Despite these measures, such products can
                            still potentially transmit disease (see <content styleCode="italics">
                        <linkHtml href="#i4i_warnings_id_9d00fa2d-3af9-4233-b932-0a0b6e7b0bb0">WARNINGS</linkHtml>
                     </content>).</paragraph>
                  <paragraph>
                     <content styleCode="italics">In vitro</content> spiking studies have been
                            used to validate the capability of the manufacturing process to remove
                            and inactivate viruses. To establish the minimum applicable virus
                            clearance capacity of the manufacturing process, these virus clearance
                            studies were performed under extreme conditions (e.g. at minimum
                            incubation times and temperatures below specifications for vapor-heat
                            treatment). Virus clearance studies for FEIBA NF performed in accordance
                            with good laboratory practices have demonstrated, that the manufacturing
                            process of FEIBA NF ensures a high margin of safety with respect to
                            adventitious viruses (<linkHtml href="#id_fab9fb4a-533b-48bb-9e69-d15a03ab6bb6">Table
                            1</linkHtml>).</paragraph>
                  <table ID="id_fab9fb4a-533b-48bb-9e69-d15a03ab6bb6" width="537">
                     <caption ID="id_e20db6e3-e6b1-4049-ad97-e05ac55d8a30">Table 1: Mean
                                    log<sub>10</sub> Reduction Factors (RFs) For Each Virus and
                                Manufacturing Step</caption>
                     <col width="16.4%"/>
                     <col width="14.3%"/>
                     <col width="8.2%"/>
                     <col width="10.2%"/>
                     <col width="15.3%"/>
                     <col width="17.3%"/>
                     <col width="9.1%"/>
                     <col width="9.1%"/>
                     <tbody>
                        <tr ID="id_6a1cd3a1-7373-4985-8ab5-da3fef3f4812">
                           <td align="center" styleCode="Botrule Toprule Rrule Lrule" valign="top">
                              <content styleCode="bold">Virus
                                        Type</content>
                           </td>
                           <td align="center" colspan="3" styleCode="Botrule Rrule" valign="top">
                              <content styleCode="bold">Enveloped
                                            RNA</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">
                              <content styleCode="bold">Enveloped DNA</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">
                              <content styleCode="bold">Non-enveloped
                                        RNA</content>
                           </td>
                           <td align="center" colspan="2" styleCode="Botrule Rrule" valign="top">
                              <content styleCode="bold">Non-enveloped
                                            DNA</content>
                           </td>
                        </tr>
                        <tr ID="id_060eb5e0-df9b-4a0a-81fa-ab9af6a83f86">
                           <td align="center" styleCode="Lrule Botrule Rrule" valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Virus
                                                Family</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Retroviridae</content>
                              </paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Botrule Rrule" valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Flaviviridae</content>
                              </paragraph>
                           </td>
                           <td align="left" styleCode="Botrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Herpesviridae</content>
                              </paragraph>
                           </td>
                           <td align="left" styleCode="Botrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Picornaviridae</content>
                              </paragraph>
                           </td>
                           <td align="left" colspan="2" styleCode="Botrule Rrule" valign="top">
                              <paragraph> </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Parvoviridae
                                        </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr ID="id_7507b5e3-00ff-4cc4-9512-761d247f127a">
                           <td align="left" styleCode="Lrule Botrule Rrule" valign="top">
                              <content styleCode="bold">Virus<footnote ID="id-0857ef75-c025-4421-ae30-5f72f348073b">Abbreviations: HIV-1, Human Immunodeficiency Virus
                                                Type 1; BVDV, Bovine Viral Diarrhea Virus (model for
                                                Hepatitis C Virus and other lipid enveloped RNA
                                                viruses); WNV, West Nile Virus; PRV, Pseudo rabies
                                                Virus (model for lipid enveloped DNA viruses,
                                                including Hepatitis B Virus); HAV, Hepatitis A
                                                Virus; MMV, Mice Minute Virus (model for non-lipid
                                                enveloped DNA viruses, including B19 virus
                                                [B19V])</footnote>
                              </content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">HIV-1</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">BVDV</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">WNV</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">PRV</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">HAV</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">B19V<footnote ID="id-a10665d2-410b-4f41-aab8-b72a5ed8d355">Reduction factor for Parvovirus B19 claimed for the
                                                Vapor Heat Treatment is based on results derived
                                                from experimental infectivity and titration
                                                assays.</footnote>
                              </content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">MMV</content>
                           </td>
                        </tr>
                        <tr ID="id_84d80fa0-8a78-4e6a-a7aa-2c47680bb2ad">
                           <td align="left" styleCode="Lrule Botrule Rrule" valign="top">
                              <content styleCode="bold">DEAE Sephadex
                                            Adsorption</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">3.2</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">1.8</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">n.d.</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">2.5</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">1.5</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">1.7</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">1.2</td>
                        </tr>
                        <tr ID="id_452b7fbe-0a85-45db-832c-cb70abe8797d">
                           <td align="left" styleCode="Lrule Botrule Rrule" valign="top">
                              <content styleCode="bold">35 nm
                                            Nanofiltration</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">&gt; 5.3</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">2.1</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">4.7</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">&gt; 5.7</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">2.6</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">0.2<content styleCode="bold">
                                 <footnote ID="id-24e36dfd-3c69-4dde-a1b5-c1282e5c7c3b">Reduction factors &lt; 1 log are not used for
                                                calculation of the overall reduction factor; n.d.
                                                (not done).</footnote>
                              </content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">1.0</td>
                        </tr>
                        <tr ID="id_58b349f1-7424-43d7-8d51-9e1c06fd31f7">
                           <td align="left" styleCode="Lrule Botrule Rrule" valign="top">
                              <content styleCode="bold">Vapor-Heat
                                            Treatment</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">&gt; 5.9</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">&gt; 5.6</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">&gt; 8.1</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">&gt; 6.7</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">&gt; 5.2</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">3.5</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">0.9<footnoteRef IDREF="id-24e36dfd-3c69-4dde-a1b5-c1282e5c7c3b"/>
                           </td>
                        </tr>
                        <tr ID="id_84eba84f-4508-47b4-8279-4d339a26f9aa">
                           <td align="left" styleCode="Lrule Botrule Rrule" valign="top">
                              <content styleCode="bold">Overall log reduction factor
                                            (ORF)</content>
                           </td>
                           <td align="center" styleCode="Rrule" valign="middle">&gt;
                                        14.4</td>
                           <td align="center" styleCode="Rrule" valign="middle">&gt;
                                        9.5</td>
                           <td align="center" styleCode="Rrule" valign="middle">&gt;
                                        12.8</td>
                           <td align="center" styleCode="Rrule" valign="middle">&gt;
                                        14.9</td>
                           <td align="center" styleCode="Rrule" valign="middle">&gt;
                                        9.3</td>
                           <td align="center" styleCode="Rrule" valign="middle">5.2</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">2.2</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20110623"/>
            </section>
         </component>
         <component>
            <section ID="i4i_clinical_studies_id_1af3a64f-b27f-4361-9bfa-b6197f10ac67">
               <id root="8723b05f-519b-444f-be47-b5dac59a043c"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>CLINICAL STUDIES</title>
               <text>
                  <paragraph>FEIBA NF is identical in formulation to FEIBA VH. Biochemical
                            and preclinical studies have confirmed the comparability of FEIBA NF and
                            FEIBA VH. </paragraph>
                  <paragraph>The safety and efficacy of FEIBA has
                            been demonstrated by two prospective clinical trials<sup>1,2</sup>. The
                            first, conducted by Sixma and collaborators, was a randomized
                            double-blind study comparing the effect of FEIBA and PROTHROMPLEX IMMUNO
                            (a non-activated prothrombin complex concentrate) in 15 patients with
                            hemophilia A and inhibitors to Factor VIII. A total of 150 bleeding
                            episodes (primarily joint and musculoskeletal plus a few mucocutaneous)
                            were treated. A single dose of 88 Units per kg of body weight was used
                            uniformly for treatments with FEIBA . The study showed that, based on
                            subjective patient evaluation, FEIBA was fully effective in 41.0% and
                            partly effective in 24.6% of episodes (i.e. combined effectiveness of
                            65.6%), while PROTHROMPLEX IMMUNO was rated fully effective in 25.0% and
                            partly effective in 21.4% of episodes (i.e. combined effectiveness of
                            46.4%).</paragraph>
                  <paragraph>The second study with FEIBA was a
                            multicenter study conducted by Hilgartner <content styleCode="italics">et al</content>
                     <sup>2</sup>. This study was conducted in 44
                            hemophilia A subjects with inhibitors, 3 hemophilia B subjects with
                            inhibitors and 2 acquired FVIII inhibitor subjects. It was designed to
                            evaluate the efficacy of FEIBA in the treatment of joint, mucous
                            membrane, musculocutaneous and emergency bleeding episodes such as
                            central nervous system hemorrhages and surgical bleedings. In 49
                            patients with inhibitor titers of greater than 5 Bethesda Units (from
                            nine co-operating hemophilia centers), 489 single doses were given for
                            the treatment of 165 bleeding episodes. The usual dosage was 50 Units
                            per kg of body weight, repeated at 12-hour intervals (6-hour intervals
                            in mucous membrane bleedings), if necessary. Bleeding was controlled in
                            153 episodes (93%). In 130 (78%) of the episodes, hemostasis was
                            achieved with one or more infusions within 36 hours. Of these, 36% were
                            controlled with one infusion within 12 hours. An additional 14% of
                            episodes responded after more than 36 hours.</paragraph>
                  <paragraph>Of
                            the 489 single doses, 18 (3.7%) caused minor transient reactions in
                            recipients. Out of 49 patients, 10 (20%) showed a rise in their
                            inhibitor titers. In 5 of these patients (10%), the rise was tenfold or
                            more. However, of these 10 patients, 3 had received Factor VIII or
                            Factor IX concentrates within 2 weeks prior to treatment with FEIBA.
                            These anamnestic rises have not been observed to interfere with the
                            efficacy of FEIBA. </paragraph>
               </text>
               <effectiveTime value="20110623"/>
            </section>
         </component>
         <component>
            <section ID="i4i_indications_id_85d15591-aad7-4285-acae-668bce945e47">
               <id root="8f3297da-13fa-4ea3-9e3c-53992a69dae6"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>FEIBA NF (Anti-Inhibitor Coagulant Complex) is indicated for
                            the control of spontaneous bleeding episodes or to cover surgical
                            interventions in hemophilia A and hemophilia B patients with
                            inhibitors.</paragraph>
                  <paragraph>Clinical experience suggests that
                            patients with a Factor VIII inhibitor titer of less than 5 B.U. may be
                            successfully treated with Antihemophilic Factor. Patients with titers
                            ranging between 5 and 10 B.U. may either be treated with Antihemophilic
                            Factor or FEIBA NF. Cases with Factor VIII inhibitor titers greater than
                            10 B.U. have generally been refractory to treatment with Antihemophilic
                            Factor.</paragraph>
                  <table ID="id_667f78ca-dd1f-4db7-b812-8ec7de12fde8" width="489.000">
                     <caption ID="id_eac4f6d3-08f6-4ac5-9878-1e9517bc0d58">Guidelines to
                                First and Second Choice Treatment</caption>
                     <col width="23.5%"/>
                     <col width="23.7%"/>
                     <col width="23.5%"/>
                     <col width="29.2%"/>
                     <tbody>
                        <tr ID="id_5daf6571-2c15-4ed4-bb57-475a52b5ed34">
                           <td align="left" styleCode="Botrule Toprule Rrule Lrule" valign="middle">Patient’s Inhibitor</td>
                           <td align="center" colspan="3" styleCode="Botrule Rrule" valign="middle">Clinical Situation</td>
                        </tr>
                        <tr ID="id_2e154da0-c69b-41c6-89a9-511e1aa89010">
                           <td align="left" styleCode="Lrule Botrule Rrule" valign="middle">Titer</td>
                           <td align="center" styleCode="Botrule Rrule" valign="bottom">Minor Bleeding</td>
                           <td align="center" styleCode="Botrule Rrule" valign="bottom">Major Bleeding</td>
                           <td align="center" styleCode="Botrule Rrule" valign="bottom">Surgery (Emergency)</td>
                        </tr>
                        <tr ID="id_7863e799-6a7b-4f39-8aa4-46ba5bd07c27">
                           <td align="left" styleCode="Lrule Botrule Rrule" valign="middle">less than 5 B.U.</td>
                           <td align="center" styleCode="Botrule Rrule" valign="bottom">AHF<footnote ID="id-cae112df-fb14-4853-b6e6-826c8da9e846">AHF =
                                            Antihemophilic Factor</footnote>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="bottom">AHF</td>
                           <td align="center" styleCode="Botrule Rrule" valign="bottom">AHF</td>
                        </tr>
                        <tr ID="id_ca4d6473-5961-4696-82df-53057f93b6c0">
                           <td align="left" styleCode="Lrule Botrule Rrule" valign="middle">5 to 10 B.U.</td>
                           <td align="center" styleCode="Botrule Rrule" valign="bottom">AHF</td>
                           <td align="center" styleCode="Botrule Rrule" valign="bottom">AHF</td>
                           <td align="center" styleCode="Botrule Rrule" valign="bottom">AHF</td>
                        </tr>
                        <tr ID="id_b63d8102-788c-4992-ae65-28a967f14967">
                           <td align="left" styleCode="Lrule Botrule Rrule" valign="middle"/>
                           <td align="center" styleCode="Botrule Rrule" valign="bottom">FEIBA NF</td>
                           <td align="center" styleCode="Botrule Rrule" valign="bottom">FEIBA NF</td>
                           <td align="center" styleCode="Botrule Rrule" valign="bottom">FEIBA NF</td>
                        </tr>
                        <tr ID="id_a2065351-f71e-4c34-a9e9-8fc2e5628662">
                           <td align="left" styleCode="Lrule Botrule Rrule" valign="middle">more than 10 B.U.</td>
                           <td align="center" styleCode="Rrule" valign="bottom">FEIBA
                                        NF</td>
                           <td align="center" styleCode="Rrule" valign="bottom">FEIBA
                                        NF</td>
                           <td align="center" styleCode="Botrule Rrule" valign="bottom">FEIBA NF</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Inadequate response to treatment may result from an
                            abnormal platelet count or impaired platelet function<sup>3-5</sup> that
                            were present before treatment with FEIBA NF, nanofiltered and
                            vapor-heated.</paragraph>
               </text>
               <effectiveTime value="20110623"/>
            </section>
         </component>
         <component>
            <section ID="i4i_contraindications_id_149271e4-75b9-4f6b-895f-c9385a50a562">
               <id root="8267e5e1-fd77-4e2e-8efe-85b120797f8f"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>The use of FEIBA NF is contraindicated:</paragraph>
                  <list listType="unordered">
                     <item>in patients who have known anaphylactic or severe hypersensitivity
                                reactions to the product. </item>
                     <item>in patients who are known to have a normal coagulation mechanism. </item>
                     <item>for the treatment of bleeding episodes resulting from coagulation
                                factor deficiencies in the absence of inhibitors to coagulation
                                factor VIII or coagulation factor IX.</item>
                     <item>in patients with significant signs of disseminated intravascular
                                coagulation (DIC).</item>
                     <item>in patients with acute thrombosis or embolism (including
                                myocardial infarction).</item>
                  </list>
               </text>
               <effectiveTime value="20110623"/>
            </section>
         </component>
         <component>
            <section ID="i4i_warnings_id_9d00fa2d-3af9-4233-b932-0a0b6e7b0bb0">
               <id root="a4742db1-79bb-452e-ab97-9355939ff6a8"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>At first sign or symptom of an infusion/hypersensitivity
                            reaction or a thrombotic/thromboembolic event, FEIBA NF administration
                            should be stopped immediately and diagnostic and therapeutic measures
                            initiated as appropriate.</paragraph>
               </text>
               <effectiveTime value="20110623"/>
               <component>
                  <section ID="i4i_warnings_id_6fd65e19-d5ef-439f-b508-4f41bc3533a0">
                     <id root="6da0a7cb-9bdd-4f4d-bbd8-743cbd3e6880"/>
                     <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
                     <title>Anaphylaxis and Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Allergic-type hypersensitivity reactions, including
                                    severe anaphylactoid reactions, have been reported following the
                                    infusion of FEIBA. The symptoms include urticaria, angioedema,
                                    gastrointestinal manifestations, bronchospasm, and hypotension;
                                    these reactions can be severe and can be systemic (e.g.,
                                    anaphylaxis with urticaria and angioedema, bronchospasm, and
                                    circulatory shock). If signs and symptoms of severe allergic
                                    reactions occur, immediately discontinue administration of FEIBA
                                    NF and provide appropriate supportive care. Have epinephrine
                                    immediately available to treat, if appropriate, any acute severe
                                    hypersensitivity reactions. Other infusion reactions, such as
                                    chills, pyrexia, and hypertension have also been reported.
                                    </paragraph>
                        <paragraph>In patients with known or suspected
                                    hypersensitivity to FEIBA NF, the expected benefit and the risk
                                    of re-exposure must be carefully weighed, taking into account
                                    the known or suspected type of the patient’s hypersensitivity
                                    (allergic or non-allergic), including potential remedial and/or
                                    preventative therapy or alternative therapeutic
                                    agents.</paragraph>
                     </text>
                     <effectiveTime value="20110623"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_warnings_id_e9100967-39ca-4a04-a0b8-4889de4fd929">
                     <id root="8b5bfe02-bfa4-4586-897f-b75c76177e33"/>
                     <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
                     <title>Thrombotic and Thromboembolic Events</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Thrombotic and thromboembolic
                                        events [including disseminated intravascular coagulation
                                        (DIC), venous thrombosis, pulmonary embolism, myocardial
                                        infarction, and stroke] have been reported following
                                        infusion of FEIBA VH or FEIBA NF, particularly following the
                                        administration of high doses and/or in patients with
                                        thrombotic risk factors</content> (see <content styleCode="italics">
                              <linkHtml href="#i4i_adverse_effects_id_8f157900-9987-46d8-a764-99abb7ccd35e">ADVERSE REACTIONS</linkHtml>
                           </content>). The possible
                                    presence of such risk factors should always be considered in
                                    patients with congenital and acquired hemophilia. Thromboembolic
                                    events are well recognized potential complications of FEIBA
                                    infusion. Many of these events occurred with doses above 200
                                    units/kg/day or in patients with other risk factors for
                                    thromboembolic events. A single dose of 100 units/kg body weight
                                    and a daily dose of 200 units/kg body weight should not be
                                    exceeded unless the severity of bleeding warrants and justifies
                                    the use of higher doses.  Patients receiving more than 100
                                    units/kg of body weight of FEIBA NF must be monitored for the
                                    development of DIC and/or symptoms of acute coronary ischemia.
                                    High doses of FEIBA NF should be given only as long as
                                    absolutely necessary to stop bleeding.
                                    </paragraph>
                        <paragraph>Patients with disseminated intravascular
                                    coagulation (DIC), advanced atherosclerotic disease, crush
                                    injury, septicemia, or concomitant treatment with recombinant
                                    factor VIIa have an increased risk of developing thrombotic
                                    events due to circulating tissue factor (TF) or predisposing
                                    coagulopathy.</paragraph>
                        <paragraph>FEIBA VH or FEIBA NF should
                                    be used with particular caution and only if there are no
                                    therapeutic alternatives in patients at risk of DIC, arterial or
                                    venous thrombosis.</paragraph>
                        <paragraph>FEIBA NF should not be
                                    given to patients with significant signs of disseminated
                                    intravascular coagulation (DIC) or fibrinolysis. Infusion of
                                    FEIBA NF should not exceed single dosage of 100 units per kg of
                                    body weight and daily doses of 200 units per kg body weight.
                                    Thrombotic events have been identified through post-marketing
                                    surveillance following FEIBA use for each of the approved
                                    indications. The incidence of thrombotic events cannot be
                                    determined from post-marketing data.</paragraph>
                     </text>
                     <effectiveTime value="20110623"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_warnings_id_81a0da0e-bd1b-4a64-9191-b01a7438f103">
                     <id root="2e9b7534-a09c-4db1-a21a-eb4dffbcf2f8"/>
                     <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
                     <title>Transmission of Infectious Agents</title>
                     <text>
                        <paragraph>FEIBA NF (Anti-Inhibitor Coagulant Complex),
                                    nanofiltered and vapor heated, is made from human plasma.
                                    Because this product is made from human blood, it may carry a
                                    risk of transmitting infectious agents, e.g., viruses, and
                                    theoretically, the variant Creutzfeldt-Jakob disease (vCJD)
                                    agent. There is also the possibility that unknown infectious
                                    agents may be present in such products. The risk that such
                                    products will transmit viruses has been reduced by screening
                                    plasma donors for prior exposure to certain viruses, by testing
                                    for the presence of certain current virus infections, and by
                                    inactivating and removing certain viruses during manufacture.
                                    Despite these measures, such products may still potentially
                                    transmit disease. </paragraph>
                        <paragraph>Record the batch number
                                    of the product every time FEIBA NF is administered to a patient,
                                    and consider appropriate vaccination (against hepatitis A and B
                                    virus) of patients who receive
                                    FEIBA NF.</paragraph>
                        <paragraph>ALL infections thought by a
                                    physician possibly to have been transmitted by this product
                                    should be reported by the physician or other healthcare
                                    providers to Baxter Healthcare Corporation, at 1-800-423-2862
                                    (in the U.S.) and/or to FDA Med Watch (1-800-FDA-1088 or
                                        <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>).</paragraph>
                     </text>
                     <effectiveTime value="20110623"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_precautions_id_7bb5d509-b6e8-4370-9ebe-c315f1d35553">
               <id root="4f7ea6b8-9d27-4893-a9c8-4988b9cecc81"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20110623"/>
               <component>
                  <section ID="i4i_precautions_general_id_46bf163a-093c-4209-87e8-a4daf2f403b7">
                     <id root="3aff2f88-64c8-48e2-8824-69cf1b56142f"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>Thrombotic and Thromboembolic Complications</title>
                     <text>
                        <paragraph>Caution should be used when administering FEIBA VH or
                                    FEIBA NF to patients with an increased risk of thromboembolic
                                    complications. These include, but are not limited to, patients
                                    with a history of coronary heart disease, liver disease,
                                    disseminated intravascular coagulation, post-operative
                                    immobilization, elderly patients and neonates. In each of these
                                    situations, the potential benefit of treatment with FEIBA VH or
                                    FEIBA NF should be weighed against the risk of these
                                    complications. (see <content styleCode="italics">WARNINGS:
                                            <linkHtml href="#i4i_warnings_id_e9100967-39ca-4a04-a0b8-4889de4fd929" title="Thrombotic and Thromboembolic Events">Thrombotic
                                            and Thromboembolic
                                    Events</linkHtml>)</content>
                        </paragraph>
                        <paragraph>Patients who
                                    receive FEIBA VH or FEIBA NF should be monitored for development
                                    of signs or symptoms of DIC, acute coronary ischemia, and signs
                                    and symptoms of other thrombotic and thromboembolic events. If
                                    clinical signs of intravascular coagulation occur, which include
                                    changes in blood pressure, changes in pulse rate, respiratory
                                    distress, chest pain and/or cough, the infusion should be
                                    stopped promptly and appropriate diagnostic and therapeutic
                                    measures are to be initiated.</paragraph>
                        <paragraph>Laboratory
                                    indications of DIC are decreased fibrinogen, decreased platelet
                                    count, and/or presence of fibrin-fibrinogen degradation products
                                    (FDP). Other indications of DIC include significantly prolonged
                                    thrombin time, prothrombin time, or partial thromboplastin
                                    time.</paragraph>
                     </text>
                     <effectiveTime value="20110623"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_precautions_id_6b3fc286-1ccc-4e57-ba17-f3b0f999a53a">
                     <id root="103e89b3-8c0a-4dc3-9329-70c86d27ef39"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>Concominant Medications</title>
                     <text>
                        <paragraph>It has been reported that FEIBA NF and
                                    antifibrinolytics have been given simultaneously without
                                    complications. No adequate and well-controlled studies of the
                                    combined or sequential use of FEIBA NF and recombinant Factor
                                    VIIa or antifibrinolytics have been conducted. The possibility
                                    of thrombotic events should be considered when systemic
                                    antifibrinolytics such as tranexamic acid and aminocaproic acid
                                    are used during treatment with FEIBA NF. It is recommended not
                                    to use antifibrinolytics until 12 hours after the administration
                                    of FEIBA NF.</paragraph>
                     </text>
                     <effectiveTime value="20110623"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_precautions_id_979847aa-5a03-472d-ad79-950292061e45">
                     <id root="af5a07ab-ea5b-41c4-b240-daa7b98812d2"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>Discordant Response to Bypassing Agents</title>
                     <text>
                        <paragraph>Due to patient-specific factors the response to a
                                    bypassing agent can vary, and in a given bleeding situation
                                    patients experiencing insufficient response to one agent may
                                    respond to another agent<sup>6</sup>.</paragraph>
                     </text>
                     <effectiveTime value="20110623"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_3245be8b-3102-4060-95fc-563809241dfe">
                     <id root="52c92198-88d8-434a-8578-e0bd252c0798"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Anamnestic Responses</title>
                     <text>
                        <paragraph>Administration of FEIBA NF to patients with inhibitors
                                    may result in an initial “anamnestic” rise in inhibitor levels.
                                    Anamnestic responses with rise in Factor VIII inhibitor titer
                                    have been observed in 20% of the cases (see <content styleCode="italics">CLINICAL STUDIES</content>). These
                                    anamnestic rises have not been observed to interfere with the
                                    efficacy of FEIBA. Upon continued administration of FEIBA NF,
                                    inhibitors may decrease over time.</paragraph>
                     </text>
                     <effectiveTime value="20110623"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_info_patients_id_7d19d19f-78e4-4525-b12f-e4ac7b63a696">
                     <id root="34eb5187-935d-49f7-bf3f-5ba93beb9115"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients</title>
                     <text>
                        <paragraph>Inform patients receiving FEIBA NF of the benefits and
                                    risks associated with treatment. Advise patients of the early
                                    signs of hypersensitivity reactions (see <content styleCode="italics">WARNINGS: Anaphylaxis and
                                        Hypersensitivity Reactions</content>). Advise patients to
                                    discontinue use of the product if these symptoms occur and seek
                                    immediate emergency treatment. </paragraph>
                        <paragraph>Some
                                    viruses, such as parvovirus B19 or hepatitis A, are particularly
                                    difficult to remove or inactivate at this time. Pregnant women
                                    and immune-compromised individuals should be informed of the
                                    symptoms of parvovirus B19 (i.e. fever, drowsiness, chills, and
                                    runny nose followed about two weeks later by a rash, and joint
                                    pain). Inform all patients of the symptoms of hepatitis A
                                    infection (i.e. several days to weeks of poor appetite,
                                    tiredness, and low-grade fever followed by nausea, vomiting, and
                                    upper abdominal pain). Dark urine and a yellowed complexion are
                                    also common symptoms of Hepatitis A infection.
                                    </paragraph>
                        <paragraph>Advise patients/caregivers to record the
                                    batch number of the product every time FEIBA NF is administered
                                    outside a healthcare setting.</paragraph>
                        <paragraph>Advise
                                    patients to report any adverse reactions or problems following
                                    FEIBA NF administration to their physician or healthcare
                                    provider.</paragraph>
                     </text>
                     <effectiveTime value="20110623"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_precautions_id_981b7380-ec42-494f-a8bd-eace7d38b36a">
                     <id root="e04fae81-7868-4668-9eb4-609e903a9c84"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>Non-Hemophilic Patients</title>
                     <text>
                        <paragraph>Non-hemophilic patients with acquired inhibitors
                                    against Factors VIII, IX or XII may have both a bleeding
                                    tendency and an increased risk of thrombosis at the same
                                    time.</paragraph>
                     </text>
                     <effectiveTime value="20110623"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_lab_tests_id_1b32940c-42da-442a-b1d2-5c5e8bb7518e">
                     <id root="a69971d3-75c3-4a46-b59e-d8a813125d75"/>
                     <code code="34075-2" codeSystem="2.16.840.1.113883.6.1" displayName="LABORATORY TESTS SECTION"/>
                     <title>Monitoring/Laboratory Tests</title>
                     <text>
                        <list listType="unordered">
                           <item>Perform a platelet count at the time of initial use of the
                                        product and if anticipated treatment responses are not
                                        achieved. A sufficient number of functionally intact
                                        platelets is considered to be necessary for the efficacy of
                                        the product.</item>
                           <item>No direct measure of hemostatic efficacy with bypassing
                                        agents is available. Coagulation tests such as whole blood
                                        clotting time (WBCT), aPTT and TEG may not correlate with
                                        clinical improvement. For this reason, attempts at
                                        normalizing these values by increasing the dose of FEIBA NF
                                        may not be successful and are strongly discouraged because
                                        of the potential hazard of producing DIC by overdose.</item>
                        </list>
                     </text>
                     <effectiveTime value="20110623"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_precautions_id_8ca17bee-7d42-460e-86de-7435570862d9">
                     <id root="e882d7ec-ffa1-496a-9e21-a5dc526ed53b"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>Drug Interactions</title>
                     <text>
                        <paragraph>No compatibility studies have been performed with FEIBA
                                    NF. Therefore, FEIBA NF must not be mixed with other medicinal
                                    products or solvents. (see Concomitant
                                Medications).</paragraph>
                     </text>
                     <effectiveTime value="20110623"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pregnancy_id_da5951c8-e133-49dd-baac-775e5a97838f">
                     <id root="280cdd40-c6c8-4d4a-90dd-a9e9b19b7d33"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy Category C</title>
                     <text>
                        <paragraph>The safety of FEIBA NF during pregnancy has not been
                                    established. Animal reproduction studies have not been conducted
                                    with FEIBA NF. It is also not known whether FEIBA NF can cause
                                    fetal harm when administered to a pregnant woman or can affect
                                    reproductive capacity. Physicians should carefully consider the
                                    potential risks and benefits for each specific patient before
                                    prescribing FEIBA NF.Pregnancy and the postpartum period are
                                    characterized by an increased risk of thrombosis, and several
                                    complications of pregnancy are associated with an increased risk
                                    of DIC.</paragraph>
                     </text>
                     <effectiveTime value="20110623"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_nursing_mothers_id_e020664d-c841-4bbd-9168-1d5431e7189b">
                     <id root="711867e7-4941-44a4-ab41-7dae0949c3cf"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>It is not known whether this drug is excreted in human
                                    milk. Because many drugs are excreted in human milk, caution
                                    should be exercised when FEIBA NF is administered to a nursing
                                    woman. Physicians should carefully consider the potential risks
                                    and benefits for each specific patient before prescribing FEIBA
                                    NF.</paragraph>
                     </text>
                     <effectiveTime value="20110623"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pediatric_use_id_b0b1eb6e-646a-44cd-8f99-66d7f15fad74">
                     <id root="a4ef2b2e-c508-4cb4-8777-363a517c7c6e"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>No data are available regarding the use of FEIBA NF in
                                    newborns.</paragraph>
                     </text>
                     <effectiveTime value="20100329"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_geriatric_use_id_15197614-a7e4-4b62-8edc-0f07b140451b">
                     <id root="300a040a-e42f-4b07-b3de-3c49b71fd583"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of FEIBA NF did not include sufficient
                                    numbers of subjects aged 65 and over to determine whether they
                                    respond differently from younger subjects.</paragraph>
                     </text>
                     <effectiveTime value="20110623"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_adverse_effects_id_8f157900-9987-46d8-a764-99abb7ccd35e">
               <id root="f86c78d3-755f-4eac-b245-6700a91adf89"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>FEIBA NF can precipitate allergic-type hypersensitivity
                            reactions; these reactions can be severe and can be systemic. Other
                            infusion reactions, such as chills, pyrexia, and hypertension have also
                            been reported.</paragraph>
               </text>
               <effectiveTime value="20110623"/>
               <component>
                  <section ID="i4i_adverse_effects_id_29551f39-b520-4879-b43d-22bf3b0ca4a4">
                     <id root="cc2bad35-95bb-4c0c-a1d0-dabc9671be52"/>
                     <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
                     <title>Adverse Reactions From Clinical Trials</title>
                     <text>
                        <paragraph>The adverse reactions presented in this section have
                                    been reported from two studies with FEIBA for the treatment of
                                    bleeding episodes in pediatric and adult patients with
                                    hemophilia A or B and inhibitors to factors VIII or IX. One
                                    study also enrolled acquired hemophilia patients with factor
                                    VIII inhibitors (4 of 49 patients).</paragraph>
                        <table ID="id_df393c14-7312-4a47-b2ff-e29790a249de" border="single" width="443">
                           <caption ID="id_e8c013bb-4112-4494-97b5-f5750ca6b879">Clinical
                                        Trial Adverse Reactions<footnote ID="id-c75a449c-be97-48d0-8be0-70c08b8058eb">A precise
                                            estimate of the rate of these adverse reactions is not
                                            possible from the available data.</footnote>
                           </caption>
                           <col width="54.0%"/>
                           <col width="45.9%"/>
                           <tbody>
                              <tr ID="id_7e477507-7937-43b8-9e4f-e26e91d3cee0">
                                 <td align="center" styleCode="Botrule Toprule Rrule Lrule" valign="top">
                                    <content styleCode="bold">System Organ Class
                                                  (SOC)</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">
                                    <content styleCode="bold">Preferred
                                                  MedDRA Term</content>
                                 </td>
                              </tr>
                              <tr ID="id_27c982f9-8531-4c11-a618-3902517c1bf6">
                                 <td align="left" styleCode="Lrule Botrule Rrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">BLOOD AND LYMPHATIC</content>
                                    </paragraph>
                                    <content styleCode="bold">SYSTEM DISORDERS</content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">Increase of inhibitor titer (anamnestic
                                                  response)<footnote ID="id-d80db11f-2bbd-439e-98ee-ef3738968229">Increase of inhibitor titer (anamnestic response)
                                                  is the rise of previously existing inhibitor
                                                  titers occurring after the administration of
                                                  FEIBA.</footnote>
                                 </td>
                              </tr>
                              <tr ID="id_3821f988-e95b-482a-a3a4-500fcf97a57f">
                                 <td align="left" styleCode="Lrule Botrule Rrule" valign="top">
                                    <content styleCode="bold">NERVOUS
                                                  SYSTEM DISORDERS</content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">
                                    <paragraph>Somnolence</paragraph>
                                    <paragraph>Dizziness</paragraph>
                                    <paragraph>Dysgeusia
                                                </paragraph>Hypoesthesia</td>
                              </tr>
                              <tr ID="id_4f0dcee2-521f-4e4c-9845-78445bba9e0f">
                                 <td align="left" styleCode="Lrule Botrule Rrule" valign="top">
                                    <content styleCode="bold">RESPIRATORY,
                                                  THORACIC, AND MEDIASTINAL DISORDERS</content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">Dyspnea</td>
                              </tr>
                              <tr ID="id_89d599bc-01f2-4d30-90a1-bdecdbecc7e1">
                                 <td align="left" styleCode="Lrule Botrule Rrule" valign="top">
                                    <content styleCode="bold">GASTROINTESTINAL DISORDERS</content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">Nausea</td>
                              </tr>
                              <tr ID="id_962c5bf6-14f5-4c9d-9bf1-307b0534d6eb">
                                 <td align="left" styleCode="Lrule Botrule Rrule" valign="top">
                                    <content styleCode="bold">GENERAL
                                                  DISORDERS AND ADMINISTRATION SITE
                                                  CONDITIONS</content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">
                                    <paragraph>Chills</paragraph>
                                    <paragraph>Pyrexia</paragraph>
                                    <paragraph>Chest
                                                  pain</paragraph>Chest discomfort</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20110623"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_adverse_effects_id_452186b5-7b25-492e-8d12-89b5952b9f59">
                     <id root="40e10300-7c22-4ca3-94a8-e787457c0a40"/>
                     <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
                     <title>Post-marketing Adverse Reactions</title>
                     <text>
                        <paragraph>The following adverse reactions have been reported in
                                    the post-marketing experience, listed by MedDRA System Organ
                                    Class (SOC), then by Preferred Term in order of severity, where
                                    feasible. Because these reactions are reported voluntarily from
                                    a population of uncertain size, it is not always possible to
                                    reliably estimate their frequency or establish a causal
                                    relationship to drug exposure.</paragraph>
                        <paragraph>BLOOD AND
                                    LYMPHATIC SYSTEM DISORDERS: Disseminated intravascular
                                    coagulation</paragraph>
                        <paragraph>IMMUNE SYSTEM DISORDERS:
                                    Anaphylactic reaction, Hypersensitivity
                                    </paragraph>
                        <paragraph>NERVOUS SYSTEM DISORDERS: Paresthesia,
                                    Thrombotic stroke, Embolic stroke,
                                    Headache</paragraph>
                        <paragraph>CARDIAC DISORDERS: Myocardial
                                    infarction, Tachycardia</paragraph>
                        <paragraph>VASCULAR
                                    DISORDERS: Thrombosis, Venous thrombosis, Arterial thrombosis,
                                    Hypotension, Hypertension,
                                    Flushing</paragraph>
                        <paragraph>RESPIRATORY, THORACIC, AND
                                    MEDIASTINAL DISORDERS: Pulmonary embolism, Bronchospasm,
                                    Wheezing, Cough</paragraph>
                        <paragraph>GASTROINTESTINAL
                                    DISORDERS: Vomiting, Diarrhea, Abdominal
                                    discomfort</paragraph>
                        <paragraph>SKIN AND SUBCUTANEOUS TISSUE
                                    DISORDERS: Angioedema, Urticaria, Pruritus,
                                    Rash</paragraph>
                        <paragraph>GENERAL DISORDERS AND ADMINISTRATION
                                    SITE CONDITIONS: Malaise, Feeling hot, Injection site
                                    pain.</paragraph>
                     </text>
                     <effectiveTime value="20110623"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_overdosage_id_fdc02012-1e7b-4a12-81b5-4bf296ea2909">
               <id root="0dffb37a-161e-4051-a87c-6abf540e4d23"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>
                  <content styleCode="bold">OVERDOSAGE<br/>
                  </content>
               </title>
               <text>
                  <paragraph> The risk of thrombotic and thromboembolic events (including
                            DIC, myocardial infarction, venous thrombosis, and pulmonary embolism)
                            may be increased with high doses of FEIBA NF. Some of the reported
                            events occurred with doses above 200 U/kg or with patients with other
                            risk factors for thromboembolic events. </paragraph>
               </text>
               <effectiveTime value="20110623"/>
            </section>
         </component>
         <component>
            <section ID="i4i_dosage_admin_id_e159a926-abe7-476c-90fd-42f4190e3c59">
               <id root="68b5a819-bead-4d81-b1a2-10b633354c04"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Treatment should be initiated and supervised by a physician
                            experienced in the management of
                            hemophilia.</paragraph>
                  <paragraph>Clinical trials <sup>1, 2
                            </sup>demonstrated that the response to treatment with FEIBA may differ
                            from patient to patient with no correlation to the patient’s inhibitor
                            titer. Response may also vary between different types of hemorrhage
                            (e.g. joint hemorrhage vs. CNS hemorrhage). As a general guideline, a
                            dosage range of 50 to 100 Units of FEIBA NF, per kg of body weight is
                            recommended. However, care should be taken to distinguish between the
                            following four indications:</paragraph>
                  <table ID="id_af7864d0-8a77-44d2-b1d2-159e7eb17624" border="none" width="443">
                     <caption ID="id_5885e69e-103d-4a03-9e24-40e6153a42a7">Dosing Guidelines
                                by Type of Hemorrhage</caption>
                     <col width="26.0%"/>
                     <col width="15.3%"/>
                     <col width="18.2%"/>
                     <col width="40.5%"/>
                     <tbody>
                        <tr ID="id_c324df21-b043-4d4b-8139-0afbcb05543f" styleCode="Toprule">
                           <td align="center" valign="top">
                              <content styleCode="bold">Indication</content>
                           </td>
                           <td align="center" styleCode="Toprule" valign="top">
                              <content styleCode="bold">Units/kg of Body Weight</content>
                           </td>
                           <td align="center" styleCode="Toprule" valign="top">
                              <content styleCode="bold">Recommended Dosing
                                        Interval</content>
                           </td>
                           <td align="center" valign="top">
                              <content styleCode="bold">Additional Information</content>
                           </td>
                        </tr>
                        <tr ID="id_ef86b926-77a8-4780-9a87-35b0191dc490">
                           <td align="left" valign="top">Joint Hemorrhage</td>
                           <td align="center" valign="top">50 - 100<footnote ID="id-7e8b6ef4-d21e-4be6-bde1-52ad9364cafd">Begin
                                            treatment with 50 units/kg. Dose may be increased to 100
                                            units/kg if hemorrhage does not stop.</footnote>
                           </td>
                           <td align="center" valign="top">12 hours</td>
                           <td align="left" valign="top">
                              <paragraph>Continue treatment
                                            until clear signs of clinical improvement appear (e.g.,
                                            relief of pain, reduction of swelling or mobilization of
                                            the joint).</paragraph>Two administrations of 100
                                        units/kg a day or a daily total dose of 200 units/kg should
                                        not normally be exceeded<footnote ID="id-85fb3450-0f38-4c3d-8b63-95dd1dcd4178">Patients
                                            receiving more than 100 units/kg of body weight of FEIBA
                                            NF must be monitored for the development of DIC and/or
                                            symptoms of acute coronary ischemia. High doses of FEIBA
                                            NF should be given only as long as absolutely necessary
                                            to stop bleeding.</footnote>.</td>
                        </tr>
                        <tr ID="id_51b0ec28-1eb5-401d-ae81-d952b82303f7">
                           <td align="left" valign="top">Mucous Membrane Bleeding</td>
                           <td align="center" valign="top">50 – 100<footnoteRef IDREF="id-7e8b6ef4-d21e-4be6-bde1-52ad9364cafd"/>
                           </td>
                           <td align="center" valign="top">6 hours</td>
                           <td align="left" valign="top">
                              <paragraph>Carefully monitor
                                            patient (i.e., examine for cecessation of visible
                                            bleeding) and perform repeated measurements of the
                                            patient’s hemoglobin/hematocrit.</paragraph>Two
                                        administrations of 100 units/kg a day or a daily total dose
                                        of 200 units/kg should not be exceeded<footnoteRef IDREF="id-85fb3450-0f38-4c3d-8b63-95dd1dcd4178"/>.</td>
                        </tr>
                        <tr ID="id_c7865520-5cb0-4961-8be9-ba49bfbc8990">
                           <td align="left" valign="top">Soft Tissue Hemorrhage<br/>(e.g.,
                                        retroperitoneal bleeding) </td>
                           <td align="center" valign="top">100</td>
                           <td align="center" valign="top">12 hours</td>
                           <td align="left" valign="top">A daily total dose of 200 units/kg
                                        should not be exceeded<footnoteRef IDREF="id-85fb3450-0f38-4c3d-8b63-95dd1dcd4178"/>.</td>
                        </tr>
                        <tr ID="id_89812cb1-c977-47e4-8e44-f47b4bcc046b" styleCode="Botrule">
                           <td align="left" valign="top">Other Severe Hemorrhage<br/>(e.g.,
                                        CNS bleeds)</td>
                           <td align="center" valign="top">100</td>
                           <td align="center" valign="top">6-12 hours</td>
                           <td align="left" valign="top">
                              <paragraph>May be indicated at
                                            6-hour intervals until clear clinical improvement is
                                            achieved.</paragraph>Single doses of 100 units/kg body
                                        weight and a daily dose of 200 units/kg body weight should
                                        not be exceeded unless the severity of bleeding warrants and
                                        justifies the use of higher doses<footnoteRef IDREF="id-85fb3450-0f38-4c3d-8b63-95dd1dcd4178"/>.</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Reconstitution</content>
                  </paragraph>
                  <paragraph>FEIBA NF contains no
                            preservatives. Aseptic technique should be used throughout the entire
                            reconstitution process and the solution should then be used
                            immediately.</paragraph>
                  <list listType="ordered">
                     <item>Allow the unopened vials of FEIBA NF (concentrate) and Sterile
                                Water for Injection (diluent) to reach room temperature (not above
                                37°C, 98°F).</item>
                     <item>Remove caps from the concentrate and diluent vials to expose
                                central portions of the rubber stoppers.</item>
                     <item>Disinfect the rubber stoppers of both vials using a germicidal
                                solution. Place the vials on an even surface and allow them to
                                dry.</item>
                     <item>Open the package of BAXJECT device by peeling away the lid without
                                touching the inside (Fig. A).</item>
                     <item>
                        <content styleCode="bold">Do not remove the device from the
                                    package</content>. Turn the package over and insert the plastic
                                spike through diluent stopper. (Fig. B). </item>
                     <item>Grip the package at its edge and pull the package off the device
                                (Fig. B). </item>
                     <item>Turn the system over, so that the vial is on top. Quickly insert
                                the other plastic spike into the FEIBA NF stopper (Fig. C). The
                                vacuum will draw the diluent into the FEIBA NF vial. <content styleCode="bold">Please make sure that the connection of the two
                                    vials should be done expeditiously to close the open fluid
                                    pathway created by the first insertion of the spike to the
                                    diluent vial.</content>
                     </item>
                     <item>Swirl gently until FEIBA NF is completely dissolved. Make sure
                                that FEIBA NF has been dissolved completely; otherwise, active
                                material will not pass through the device filter. </item>
                  </list>
                  <renderMultiMedia referencedObject="id_51c47c04-2f78-4b82-9e60-fd1a9d08cb81">
                     <caption ID="id_dde3c346-f0bf-404b-8d00-156b5e8b127c">Fig A</caption>
                  </renderMultiMedia>
                  <renderMultiMedia referencedObject="id_95c8a3dc-aa0e-4d69-bb82-5e22d823124f">
                     <caption ID="id_30a8bd71-fe8b-4671-a428-881a41681f7c">Fig B</caption>
                  </renderMultiMedia>
                  <renderMultiMedia referencedObject="id_822aaf3f-6f48-4327-a158-68fc0f0d50ce">
                     <caption ID="id_08bbbc5e-ae8a-4500-80aa-069c341dcc4b">Fig C</caption>
                  </renderMultiMedia>
                  <paragraph>
                     <content styleCode="bold">Do not refrigerate
                                after reconstitution!</content>
                  </paragraph>
                  <paragraph>After complete reconstitution of FEIBA NF its
                            injection or infusion should be commenced as promptly as practicable,
                            but must be completed within three hours following reconstitution. The
                            solution must be given by intravenous injection or intravenous drip
                            infusion.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rate of
                                Administration:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">The </content>
                     <content styleCode="bold">maximum
                                injection or infusion rate must not exceed 2 units per kg of body
                                weight per minute</content>. For a patient with a body weight of 75
                            kg, this corresponds to an infusion rate of 2.5 - 7.5 mL per minute
                            depending on the number of units per vial (see label on
                            vial).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Intravenous
                                Injection or Infusion:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Inspect for particulate matter and discoloration after
                                reconstituting the concentrate as described under <content styleCode="italics">Reconstitution</content> prior to
                                administration. The appearance of the solution should be colorless
                                to slightly yellowish and essentially free of visible particles. Do
                                not use solutions that are cloudy or have deposits.</item>
                     <item>Mixing of FEIBA NF with other products or substances must be
                                avoided. It is advisable to flush venous access lines with isotonic
                                saline prior to and after infusion of FEIBA NF.</item>
                     <item>If devices other than those supplied with FEIBA NF are used,
                                ensure use of an adequate filter.</item>
                     <item>Plastic Luer lock syringes are recommended for use with this
                                product since protein such as FEIBA NF tends to stick to the surface
                                of all-glass syringes.</item>
                  </list>
                  <list listType="ordered">
                     <item>Turn the BAXJECT device handle down towards the FEIBA NF
                                concentrate vial and remove the cap attached to the syringe
                                connection of the BAXJECT device (Fig. D).</item>
                     <item>Draw air into the syringe, connect the syringe to the BAXJECT
                                device, inject air into the concentrate vial (Fig. E).</item>
                     <item>While keeping the syringe plunger in place, turn the system upside
                                down (concentrate vial now on top). Draw the concentrate into the
                                syringe by pulling the plunger back slowly (Fig. F).</item>
                     <item>Turn the BAXJECT handle to its original position (facing side
                                way).</item>
                     <item>Disconnect the syringe, attach a suitable needle and inject or
                                infuse intravenously as instructed under <content styleCode="italics">Rate of
                                    Administration.</content>
                        <paragraph>.</paragraph>
                     </item>
                  </list>
                  <renderMultiMedia referencedObject="id_f98fe8d1-4ce0-4793-ac37-29d79ce3d2b9">
                     <caption ID="id_334b39f1-0649-4cb9-8910-513eddc5c76e">Fig D</caption>
                  </renderMultiMedia>
                  <renderMultiMedia referencedObject="id_f71646cb-9d0d-46a3-b3a1-0ac689feb9c5">
                     <caption ID="id_e7a135a9-ab60-4261-988b-8b1a8c2724d3">Fig E</caption>
                  </renderMultiMedia>
                  <renderMultiMedia referencedObject="id_861c3f81-eb7c-4e48-a95b-51e52ccb652d">
                     <caption ID="id_43a11eb0-0d37-42fb-a771-8751c9b63878">Fig F</caption>
                  </renderMultiMedia>
               </text>
               <effectiveTime value="20110623"/>
               <component>
                  <observationMedia ID="id_51c47c04-2f78-4b82-9e60-fd1a9d08cb81">
                     <text>Open the package of BAXJECT device by peeling away the lid without
                                touching the inside.</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bdffc8e-b908-4827-b941-31a1f7063125-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="id_95c8a3dc-aa0e-4d69-bb82-5e22d823124f">
                     <text>¬Do not remove the device from the package.¬ Turn the package over
                                and insert the plastic spike through diluent stopper</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bdffc8e-b908-4827-b941-31a1f7063125-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="id_822aaf3f-6f48-4327-a158-68fc0f0d50ce">
                     <text>Turn the system over, so that the vial is on top. Quickly insert
                                the other plastic spike into the FEIBA NF stopper.</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bdffc8e-b908-4827-b941-31a1f7063125-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="id_f98fe8d1-4ce0-4793-ac37-29d79ce3d2b9">
                     <text>Turn the BAXJECT device handle down towards the FEIBA NF
                                concentrate vial and remove the cap attached to the syringe
                                connection of the BAXJECT device</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bdffc8e-b908-4827-b941-31a1f7063125-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="id_f71646cb-9d0d-46a3-b3a1-0ac689feb9c5">
                     <text>Draw air into the syringe, connect the syringe to the BAXJECT
                                device, inject air into the concentrate vial</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bdffc8e-b908-4827-b941-31a1f7063125-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="id_861c3f81-eb7c-4e48-a95b-51e52ccb652d">
                     <text>While keeping the syringe plunger in place, turn the system upside
                                down (concentrate vial now on top). Draw the concentrate into the
                                syringe by pulling the plunger back slowly</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bdffc8e-b908-4827-b941-31a1f7063125-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_how_supplied_id_d5da944b-6c04-4c7d-90de-212aa8152a31">
               <id root="b0500dba-fa59-4a99-8945-d2935b74b023"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>FEIBA NF is available in single-dose vials in the following
                            nominal dosage strengths:</paragraph>
                  <paragraph>Blue - 500 Units per
                            vial (NDC 64193-223-02)</paragraph>
                  <paragraph>Green - 1000 Units per
                            vial (NDC 64193-224-02)</paragraph>
                  <paragraph>Purple - 2500 Units per
                            vial (NDC 64193-225-02)</paragraph>
                  <paragraph>The number of Units of
                            Factor VIII inhibitor bypassing activity is stated on the label of each
                            vial.</paragraph>
                  <paragraph>FEIBA NF is packaged with a suitable volume
                            (20 mL or 50 mL) of Sterile Water for Injection, U.S.P., one BAXJECT
                            Needleless Transfer Device, and one Package
                                Insert.</paragraph>
                  <paragraph>
                     <content styleCode="bold">The 50 mL
                                SWFI stoppers are not latex-free and may contain Dry Natural Rubber
                                Latex.</content>
                  </paragraph>
                  <paragraph> </paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage</content>
                  </paragraph>
                  <paragraph>Store at
                            room temperature, not to exceed 25°C
                                (77°F).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Avoid
                                freezing, which may damage the diluent
                                vial.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Store in the original package in order to protect from
                                light.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20110623"/>
            </section>
         </component>
         <component>
            <section ID="i4i_references_id_affc5edf-9bd4-4c1b-ab36-81a427e7f93e">
               <id root="094620f1-4793-4178-a120-8bd6559ba936"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>REFERENCES</title>
               <text>
                  <list listType="ordered">
                     <item>Sjamsoedin L. J. M., Heijnen L., Mauser-Bunschoten E. P., van
                                Geijlswijk J. L., van Houwelingen H., van Asten P., Sixma J. J.: The
                                Effect of Activated Prothrombin-Complex Concentrate (FEIBA) on Joint
                                and Muscle Bleeding in Patients with Hemophilia A and Antibodies to
                                Factor VIII. The New Engl. J. of Med. 305: 717, 1981.</item>
                     <item>Hilgartner M. W., Knatterud G. AND THE FEIBA STUDY GROUP: The Use
                                of Factor-Eight-Inhibitor-By-Passing-Activity (FEIBA IMMUNO) Product
                                for Treatment of Bleeding Episodes in Hemophiliacs with Inhibitors.
                                Blood 61: 36, 1983.</item>
                     <item>Vermylen J., Schetz J., Semeraro N., Mertens F., Verstraete M.:
                                Evidence that ‘Activated’ Prothrombin Concentrates Enhance Platelet
                                Coagulant Activity. Brit. J. Haematol. 38: 235, 1978.</item>
                     <item>Semeraro N., Vermylen J.: Evidence that Washed Human Platelets
                                Possess Factor-X Activator Activity. Brit. J. Haematol. 36: 107,
                                1977.</item>
                     <item>Wensley R. T.: General Summary of the Use of FEIBA in
                                Haemophiliacs with Inhibitors to FVIII. Presentation at the Second
                                Workshop on Factor VIII Inhibitor Patients, Vienna, 1979.</item>
                     <item>Astermark, J., Donfield, S.M., DiMichele, D.M., Gringeri, A.,
                                Gilbert, S.A., Waters, J. and Berntorp, E.: A randomized comparison
                                of bypassing agents in haemophilia complicated by an inhibitor: the
                                FEIBA NovoSeven Comparative ( FENOC) Study.: Blood, 109:546,
                                2007.<paragraph/>
                     </item>
                  </list>
                  <paragraph>To enroll in the confidential, Industry-wide Patient
                            Notification System, </paragraph>
                  <paragraph>Call 1-888-UPDATE
                            U(1-888-873-2838).</paragraph>
                  <paragraph>Baxter, Feiba and Prothromplex
                            are trademarks of Baxter AG, Vienna, Austria. Baxter, Feiba and Baxject
                            are trademarks of Baxter International Inc., registered in the U.S.
                            Patent and Trademark Office.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Baxter Healthcare Corporation</content>
                  </paragraph>
                  <paragraph>Westlake Village, CA 91362 USA
                            </paragraph>
                  <paragraph>U.S. License No.
                            140</paragraph>
                  <paragraph>Revised Feb 2011</paragraph>
               </text>
               <effectiveTime value="20110623"/>
            </section>
         </component>
         <component>
            <section ID="i4i_Principal_display_panel_id_d06d68fc-2b85-43fb-aed1-8a0013fab99a">
               <id root="0b23b2ee-8fb1-4d19-8cf3-e571e5554e4a"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Principle Display Panel</title>
               <text>
                  <renderMultiMedia referencedObject="id_d051554a-6c58-4472-832a-1cfcd3797cbb">
                     <caption ID="id_a091d660-1a54-4503-8534-069f381a3dd1">FEIBA NF 500U vial
                                label</caption>
                  </renderMultiMedia>
                  <paragraph>20 mL size, dried </paragraph>
                  <paragraph>NDC
                            64193-323-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">Anti-Inhibitor Coagulant
                                Complex</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FEIBA NF</content>
                  </paragraph>
                  <paragraph>Nanofiltered &amp; Vapor
                            Heated</paragraph>
                  <paragraph>
                     <content styleCode="bold">Baxter
                            </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For
                                Intravenous Use Only </content>
                  </paragraph>
                  <paragraph>Contains no
                            preservative</paragraph>
                  <paragraph>
                     <content styleCode="bold">Dosage
                                &amp; Administration</content>: See accompanying package
                            insert</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage</content>: Store at room temperature not to exceed 25°C
                            (77°F).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Reconstitution</content>: Use 20 mL sWFI, U.S.P.; Keep at room
                            temperature not to exceed 25°C (77°F); Use within 3 hours of
                            reconstitution</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx
                                only</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="id_f0f92d92-a2b0-48c3-9f54-af70816f65be">
                     <caption ID="id_b3cc667f-9fd2-46fa-8ffc-617c0a3f959a">FEIBA NF 500U unit
                                carton</caption>
                  </renderMultiMedia>
                  <paragraph>20 mL size, dried </paragraph>
                  <paragraph>NDC
                            64193-223-02</paragraph>
                  <paragraph>
                     <content styleCode="bold">Anti-Inhibitor Coagulant
                                Complex</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FEIBA NF</content>
                  </paragraph>
                  <paragraph>Nanofiltered &amp; Vapor
                            Heated</paragraph>
                  <paragraph>
                     <content styleCode="bold">Baxter
                            </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For
                                Intravenous Use Only</content>
                  </paragraph>
                  <paragraph>Contains no
                                preservative</paragraph>
                  <paragraph>
                     <content styleCode="bold">Dosage
                                &amp; Administration</content>: See accompanying package
                            insert</paragraph>
                  <paragraph>Storage: Store at room temperature not to
                            exceed 25°C (77°F). Store in the original package in order to protect
                            from light.</paragraph>
                  <paragraph>Reconstitution: Use 20 mL sWFI,
                            U.S.P.; Keep at room temperature not to exceed 25°C (77°F); Use within 3
                            hours of reconstitution</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do Not Freeze</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>Includes BAXJECT Needleless Transfer
                            Device</paragraph>
                  <renderMultiMedia referencedObject="id_c1e866c0-bba3-4d40-a59f-4d926640138d">
                     <caption ID="id_2b89c9f0-df32-4a5d-a54c-1740ba672455">20 mL Sterile
                                Water for Injection</caption>
                  </renderMultiMedia>
                  <paragraph>1A7141</paragraph>
                  <paragraph>NDC
                            0338-0764-02</paragraph>
                  <paragraph>20 mL Single-Dose Container
                            Nonpyrogenic</paragraph>
                  <paragraph>
                     <content styleCode="bold">Sterile
                                Water for Injection, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">for reconstitution of accompanying
                                product</content>
                  </paragraph>
                  <paragraph>Do not use unless clear. No
                            antimicrobial agent or other substance has been added. Do not use for
                            intravascular injection without making approximately isotonic by
                            addition of suitable solute. Discard unused portion. Rx Only. This
                            Product Contains Dry Natural Rubber.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Baxter</content>
                  </paragraph>
                  <paragraph>Manufactured
                            by</paragraph>
                  <paragraph>
                     <content styleCode="bold">Baxter Healthcare
                                Corporation</content>
                  </paragraph>
                  <paragraph>Deerfield, IL 60015
                            USA</paragraph>
               </text>
               <effectiveTime value="20110623"/>
               <component>
                  <observationMedia ID="id_d051554a-6c58-4472-832a-1cfcd3797cbb">
                     <text>FEIBA NF 500U vial label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bdffc8e-b908-4827-b941-31a1f7063125-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="id_f0f92d92-a2b0-48c3-9f54-af70816f65be">
                     <text>FEIBA NF 500U unit carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bdffc8e-b908-4827-b941-31a1f7063125-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="id_c1e866c0-bba3-4d40-a59f-4d926640138d">
                     <text>20 mL Sterile Water for Injection</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bdffc8e-b908-4827-b941-31a1f7063125-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>